Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib and Entospletinib +/- Obinutuzumab in Relapsed/Refractory CLL
NCT02983617Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirabrutinib and entospletinib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Rate of Complete Remission/Complete Remission With Incomplete Recovery of the Bone Marrow at Week 25. Started Apr 2017; status: completed.
02
Drugs
tirabrutinibentospletinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02983617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983617.